Hopp til innhold
NHI.no
Annonse
Informasjon

Skallethet hos menn

Skallethet rammer de fleste menn, men tidspunktet for når denne prosessen starter, og hvor raskt hårtapet utvikler seg, varierer.

Skallethet, mannlig.jpg
Skallethet skyldes en arvelig bestemt økt følsomhet overfor mannlige kjønnshormoner.

Sist oppdatert:

18. mars 2019

Innhold i artikkelen

Hva er skallethet?

Dette er den vanligste formen for hårtap, såkalt androgen alopesi. De aller fleste menn får denne typen hårtap, men tidspunktet når prosessen starter, varierer sterkt. Hos fem prosent starter hårtapet før 20 års alder. Det begynner vanligvis ved tinningene og noe senere over issen.

Annonse

Tilstanden oppfattes som et normalfenomen og skyldes en arvelig bestemt økt følsomhet overfor mannlige kjønnshormoner (androgener).

Animasjon av hårtap

Vil du vite mer

Dette dokumentet er basert på det profesjonelle dokumentet Skallethet, mannlig . Referanselisten for dette dokumentet vises nedenfor

  1. Jensen Gjersvik P. Mannlig skallethet. Tidsskr Nor Lægeforen 2000; 120: 1120. Tidsskrift for Den norske legeforening
  2. Feinstein RP. Androgenetic alopecia. Medscape, last updated Feb 12, 2018. emedicine.medscape.com
  3. Stough D, Stenn K, Haber R, et al. Psychological effect, pathophysiology, and management of androgenetic alopecia in men. Mayo Clin Proc. 2005 Oct. 80(10):1316-22.
  4. Donovan J, Goldstein BG, Goldstein AO. Androgenetic alopecia in men: Pathogenesis, clinical features, and diagnosis. UpToDate, last updated Jan 30, 2019. UpToDate
  5. Mounsey AL, Reed SW. Diagnosing and treating hair loss. Am Fam Physician 2009; 80: 356-62. American Family Physician
  6. Barth JH. Should men still go bald gracefully? Lancet 2000; 355: 161-2. PubMed
  7. Vierhapper H, Nowotny P, Maier H, Waldhäusl W. Production rates of dihydrotestosterone in healthy men and women and in men with male pattern baldness: determination by stable isotope/dilution and mass spectrometry. J Clin Endocrinol Metab 2001; 86: 5762. PubMed
  8. Haber R. Androgenic alopecia. BestPractice, last updated March 2018. bestpractice.bmj.com
  9. Varothai S, Bergfeld WF. Androgenetic alopecia: an evidence-based treatment update. Am J Clin Dermatol. 2014;15(3):217-30. doi: 10.1007/s40257-014-0077-5. DOI
  10. Mella JM, Perret MC, Manzotti M, et al. Efficacy and safety of finasteride therapy for androgenetic alopecia: a systematic review. Arch Dermatol 2010; 146:1141. PubMed
  11. Price VH, Menefee E, Sanchez M, Kaufmann KD. Changes in hair weight in men with androgenetic alopecia after treatment with finasteride (1 mg daily): three-and 4-year results. Am Acad Dermatol 2006; 55: 71-4. PubMed
  12. Arca E, Acikgøz G, Tastan HB et al. An open, randomized, comparative study of oral finasteride and 5% topical minoxidil in male androgenetic alopecia. Dermatology 2004; 209: 117-25. PubMed
  13. Leyden J, Dunlap F, Miller B, et al. Finasteride in the treatment of men with frontal male pattern hair loss. J Am Acad Dermatol 1999; 40: 930–7.
  14. Olsen EA, Dunlap FE, Funicella T, et al. A randomized clinical trial of 5% topical minoxidil versus 2% topical minoxidil and placebo in the treatment of androgenetic alopecia in men. J Am Acad Dermatol 2002; 47: 377–85.
  15. Springer K, Brown M, Stulberg DL. Common hair loss disorders. Am Fam Physician 2003; 68: 93-102. PubMed
  16. D'Amico AV, Roehrborn CG. Effect of 1 mg/day finasteride on concentrations of serum prostate-specific antigen in men with androgenic alopecia: a randomised controlled trial. Lancet Oncol 2007; 8: 21-5. PubMed
Annonse
Annonse